Osteoporosis is a chronic disease in
which the bone density and bone mass is reduced to such an extent that
the bones and cartilages become more prone to cracks and fractures. In
osteoporosis, the microstructure of bones and amount and number of
various proteins is depleted, that leads to not only rise in brittleness
and porosity of bones but also failure of bones to regenerate. This
condition leads to chronic pain and illness, which could be fatal.
Osteoporosis drugs market is semi-consolidated market and the demand for
various drugs (inclusive of generic and branded) is increasing at a
slow pace, due to steady growth in the prevalence of the disease across
the globe. This report is focused towards identifying the current
scenario as well as the future market potential for osteoporosis drugs
globally. The global osteoporosis drugs market is segmented on the basis
of drugs classes available for the treatment of osteoporosis, such as,
bisphosphonates, RANK ligand inhibitors (denosumab), calcitonin,
parathyroid hormone therapy (PTH), selective estrogen receptor
inhibitors (SERMs) and others (estrogen therapy and calcium and vitamin
D).
Report Overview @ https://www.transparencymarketresearch.com/osteoporosis-drug-market.html
Bisphosphonates is identified as the largest segment, with a share
of 48.2% of the total osteoporosis drugs market, as of 2013. Whereas,
pipeline drugs is identified as the fastest growing segment growing at a
CAGR of 125.2%, during the study period from 2014 to 2020. Rising
population of osteoporosis patients across the globe is identified as
the major driver of this market, followed by introduction of new drug
classes. According to International Osteoporosis Foundation (IOF), every
year, osteoporosis causes more than 9 million fractures and bone cracks
across the globe. Further, it also stated that, around 200 million
women throughout the world are being affected by osteoporosis every
year. Thus, increasing prevalence of the disease is considered as an
important growth propeller of the market. In addition, introduction of
new drug classes to overcome threat of generics and chronic side effects
caused by established drugs (brands) is another factor accentuating the
growth of osteoporosis drugs market. Recently, new drug classes, such
as, parathyroid hormone therapy (PTH) (2008) and denosumab (2010) have
been introduced in the market. Due to minimal side effects of the drugs
that belong to these classes, the demand and focus of treatment has been
shifted towards these treatments. In addition, pipeline products such
as, Odanacatib, Romosozumab and BA058-SC are estimated to propel the
growth of the market after their regulatory approvals. This growth is
likely to observe due to the distinct advantages of these drugs over
existing drugs and formulations. The forecast for these products is
estimated considering their expected approval and commercialization
years.
Request A Sample Copy @ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=133
Geographically, the osteoporosis drugs market is segmented as North
America, Europe, Asia-Pacific and Rest of the World (RoW). Presently,
the North American region is the largest market in the world, owing to
the presence of large number of osteoporosis patients, world-class
medical infrastructure, rising awareness about the disease and its
treatment and proper utilization of technologically sound devices for
diagnosis purpose. However, Asia-Pacific region is considered as the
most promising market during the forecast period from 2014 to 2020. The
growth is mainly attributed to factors such as steadily increasing
incidence rate of osteoporosis, increasing medical expenditure,
increased healthcare awareness towards diagnosis and treatment of
osteoporosis and dietary habits and lack of nutritious foods.
The osteoporosis drugs market is considered as semi-consolidated
and is dominated by selective players. More than 63% of the total market
share is held by market players such as, Eli Lilly and Company, Pfizer,
Inc., Amgen, Inc., Merck & Co., Inc. and Novartis International AG.
These players, due to their effective products, dominate the entire
market. In addition, other players include F. Hoffmann La Roche Ltd.,
Actavis plc, Teva Pharmaceutical Industries Ltd. and Novo Nordisk A/S.
which contributed to the market with their generic formulations.
No comments:
Post a Comment